The mitogen-activated protein kinases (MAPKs) participate in a multitude of processes that control hepatic metabolism. The liver regulates glucose and lipid metabolism and under pathophysiological conditions, such as obesity, type 2 diabetes mellitus, and non-alcoholic fatty liver disease these processes become dysfunctional. Stress responses activate the hepatic MAPKs which, is thought to impair insulin action and lipid metabolism. The MAPKs also activate the MAPK phosphatases which, oppose their actions. How the MAPK/MKP balance is controlled in liver metabolism and how perturbations in these activities contribute to metabolic disease remains unclear. A discussion of recent insights into the MAPK/MKP signaling role in hepatic metabolic function and disease will be the focus of this review.

The liver plays a critical role in glucose metabolism and communicates with peripheral tissues to maintain energy homeostasis. Obesity and insulin resistance are highly associated with nonalcoholic fatty liver disease (NAFLD). However, the precise molecular details of NAFLD remain incomplete. The p38 mitogen-activated protein kinase (MAPK) and c-Jun NH 2 -terminal kinase (JNK) regulate liver metabolism. However, the physiological contribution of MAPK phosphatase 1 (MKP-1) as a nuclear antagonist of both p38 MAPK and JNK in the liver is unknown. Here we show that hepatic MKP-1 becomes overexpressed following high-fat feeding. Liver-specific deletion of MKP-1 enhances gluconeogenesis and causes hepatic insulin resistance in chow-fed mice while selectively conferring protection from hepatosteatosis upon high-fat feeding. Further, hepatic MKP-1 regulates both interleukin-6 (IL-6) and fibroblast growth factor 21 (FGF21). Mice lacking hepatic MKP-1 exhibit reduced circulating IL-6 and FGF21 levels that were associated with impaired skeletal muscle mitochondrial oxidation and susceptibility to diet-induced obesity. Hence, hepatic MKP-1 serves as a selective regulator of MAPK-dependent signals that contributes to the maintenance of glucose homeostasis and peripheral tissue energy balance. These results also demonstrate that hepatic MKP-1 overexpression in obesity is causally linked to the promotion of hepatosteatosis. O besity is a major problem globally, and its incidence is increasing at an alarming rate (1). Obesity predisposes to the development of nonalcoholic fatty liver disease (NAFLD), which is a spectrum of liver-related pathologies that encompasses steatosis, nonalcoholic steatosis, and nonalcoholic steatohepatitis (2). The development of hepatosteatosis arises as a result of an imbalance between triglyceride deposition and removal. Epidemiologically, NAFLD is associated with type 2 diabetes, suggesting that hepatosteatosis and the development of insulin resistance are causally linked (2). However, both genetic mouse models and clinical data suggest dissociation of hepatosteatosis from insulin resistance, arguing against the existence of such a causal link (3). Several proposed mechanisms have been put forth to explain the relationship between hepatosteatosis and insulin resistance. One mechanism proposes that type 2 diabetes results in hyperinsulinemia, which promotes hepatic lipogenesis and thus hepatosteatosis. Dysfunction in hepatic lipid metabolism and lipotoxicity have also been proposed to activate serine/threonine kinases that subsequently lead to the failure of insulin to signal (4).The actions of kinases in physiological and pathophysiological metabolic pathways have been studied extensively (5, 6). In particular, the mitogen-activated protein kinase (MAPK) pathway is an established regulator of hepatic metabolism (7-10). The stressresponsive MAPK c-Jun NH 2 -terminal kinase 1 (JNK1), when deleted specifically in the liver, results in the development of hepatosteatosis, enhanced hepatic glucose produ...

Stress responses promote obesity and insulin resistance, in part, by activating the stress-responsive mitogen-activated protein kinases (MAPKs), p38 MAPK, and c-Jun NH-terminal kinase (JNK). Stress also induces expression of MAPK phosphatase-1 (MKP-1), which inactivates both JNK and p38 MAPK. However, the equilibrium between JNK/p38 MAPK and MKP-1 signaling in the development of obesity and insulin resistance is unclear. Skeletal muscle is a major tissue involved in energy expenditure and glucose metabolism. In skeletal muscle, MKP-1 is upregulated in high-fat diet-fed mice and in skeletal muscle of obese humans. Mice lacking skeletal muscle expression of MKP-1 (MKP1-MKO) showed increased skeletal muscle p38 MAPK and JNK activities and were resistant to the development of diet-induced obesity. MKP1-MKO mice exhibited increased whole-body energy expenditure that was associated with elevated levels of myofiber-associated mitochondrial oxygen consumption. miR-21, a negative regulator of PTEN expression, was upregulated in skeletal muscle of MKP1-MKO mice, resulting in increased Akt activity consistent with enhanced insulin sensitivity. Our results demonstrate that skeletal muscle MKP-1 represents a critical signaling node through which inactivation of the p38 MAPK/JNK module promotes obesity and insulin resistance.

The balance of protein phosphorylation is achieved through the actions of a family of protein serine/threonine kinases called the mitogen-activated protein kinases (MAPKs). The propagation of MAPK signals is attenuated through the actions of the MAPK phosphatases (MKPs). The MKPs specifically inactivate the MAPKs by direct dephosphorylation. The archetypal MKP family member, MKP-1 has garnered much of the attention amongst its ten other MKP family members. Initially viewed to play a redundant role in the control of MAPK signaling, it is now clear that MKP-1 exerts profound regulatory functions on the immune, metabolic, musculoskeletal and nervous systems. This review focuses on the physiological functions of MKP-1 that have been revealed using mouse genetic approaches. The implications from studies using MKP-1-deficient mice to uncover the role of MKP-1 in disease will be discussed.

Mitogen-activated protein kinase phosphatase-2 (MKP-2The amplitude and duration of MAP kinase signaling within a specific subcellular compartment are key features in the integration of extracellular stimuli and their effects on cellular (1). Three main MAP kinase groups, the ERKs, JNK, and p38 MAP kinases, are involved in regulating functions such as proliferation, apoptosis, and differentiation in response to growth factors, peptide hormones, stress, and infection (2). Perturbations in MAP kinase signaling are features of several different types of diseases including several types of cancers (3), diabetes (4), atherosclerosis (5, 6), and immune disorders.The kinetics of MAP kinase activation are strictly controlled principally by the mitogen-activated protein kinase phosphatases (MKPs), 3 a family of at least 10 dual specific phosphatases (DUSPs) that function to terminate MAP kinase signaling within a defined subcellular location (7). They share a common C-terminal catalytic domain and an N-terminal non-catalytic domain containing the MAP kinase interaction motif (8). Each isoform has unique yet overlapping features including substrate specificity, subcellular distribution, and factors regulating induction. For example, MKP-1 is a nuclear DUSP of the type 1 class and selective for all three major MAP kinases in vitro, whereas MKP-3, a type II DUSP, is a cytosolic phosphatase selective solely for ERK over the other kinases (7). Due to effects upon MAP kinase signaling, pertubations in the MKPs have been implicated principally in cancer (9). However, more recently, a role has been established in inflammation (10) and some cardiovascular disorders (11).One poorly studied MKP is MKP-2 (12). This DUSP (DUSP-4) is a member of the type 1 family and has been shown to be induced in response to a number of stimuli including phorbol esters and growth hormones (12-14). Nuclear targeting is regulated by two distinct nuclear targeting sequences (15). Substrate specificity for ERK and JNK was originally demonstrated in vitro (16); however, selective inhibition of JNK has been implicated in cellular studies (17,18). Although MKP-2 has been recently regarded as a surrogate for the more well described MKP-1, recent cellular studies demonstrate a role in protection against apoptosis (17) and in senescence (19). However, there is still a lack of information describing the function of DUSP-4 in different cell types, in particular regarding substrate selectivity in vivo.We have recently developed a DUSP-4 deletion mouse model and demonstrated a novel immunological phenotype in vivo (20). Using embryonic fibroblasts from DUSP-4 deletion mice, we now examine the effect of deletion upon MAP kinase signaling and growth parameters. We find that despite very moderate increases in ERK and JNK activity, MKP-2 deletion has profound effects upon cellular proliferation. In particular, we identify a role for MKP-2 in G 2 /M phase transition and demonstrate that MKP-2 plays a role in cell survival in response to the apo-* This work was supporte...